These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
328 related articles for article (PubMed ID: 32567703)
21. A novel inhibitor of monooxygenase reversed the activity of tetracyclines against tet(X3)/tet(X4)-positive bacteria. Xu L; Zhou Y; Niu S; Liu Z; Zou Y; Yang Y; Feng H; Liu D; Niu X; Deng X; Wang Y; Wang J EBioMedicine; 2022 Apr; 78():103943. PubMed ID: 35306337 [TBL] [Abstract][Full Text] [Related]
22. Novel Tet(L) Efflux Pump Variants Conferring Resistance to Tigecycline and Eravacycline in Staphylococcus Spp. Wang N; Li D; Schwarz S; Qin S; Yao H; Du XD Microbiol Spectr; 2021 Dec; 9(3):e0131021. PubMed ID: 34878306 [TBL] [Abstract][Full Text] [Related]
23. Emergence of a Plasmid-Encoded Resistance-Nodulation-Division Efflux Pump Conferring Resistance to Multiple Drugs, Including Tigecycline, in Klebsiella pneumoniae. Lv L; Wan M; Wang C; Gao X; Yang Q; Partridge SR; Wang Y; Zong Z; Doi Y; Shen J; Jia P; Song Q; Zhang Q; Yang J; Huang X; Wang M; Liu JH mBio; 2020 Mar; 11(2):. PubMed ID: 32127452 [TBL] [Abstract][Full Text] [Related]
24. A novel plasmid from Aerococcus urinaeequi of porcine origin co-harboring the tetracycline resistance genes tet(58) and tet(61). Yang Q; Zhu Y; Schwarz S; Wang L; Liu W; Yang W; Luan T; Liu S; Zhang W Vet Microbiol; 2021 Jun; 257():109065. PubMed ID: 33866063 [TBL] [Abstract][Full Text] [Related]
25. Tigecycline resistance in clinical isolates of Enterococcus faecium is mediated by an upregulation of plasmid-encoded tetracycline determinants tet(L) and tet(M). Fiedler S; Bender JK; Klare I; Halbedel S; Grohmann E; Szewzyk U; Werner G J Antimicrob Chemother; 2016 Apr; 71(4):871-81. PubMed ID: 26682961 [TBL] [Abstract][Full Text] [Related]
26. Potential of Tetracycline Resistance Proteins To Evolve Tigecycline Resistance. Linkevicius M; Sandegren L; Andersson DI Antimicrob Agents Chemother; 2016 Feb; 60(2):789-96. PubMed ID: 26596936 [TBL] [Abstract][Full Text] [Related]
27. Multiple Mechanisms of Tigecycline Resistance in Wang J; Wu H; Mei CY; Wang Y; Wang ZY; Lu MJ; Pan ZM; Jiao X Microbiol Spectr; 2021 Oct; 9(2):e0041621. PubMed ID: 34523976 [TBL] [Abstract][Full Text] [Related]
28. Omadacycline invitro activity against a molecularly characterized collection of clinical isolates with known acquired tetracycline resistance mechanisms. Mendes RE; Huband MD; Streit JM; Castanheira M; Flamm RK Diagn Microbiol Infect Dis; 2020 Jul; 97(3):115054. PubMed ID: 32376058 [TBL] [Abstract][Full Text] [Related]
29. High Levels of Intrinsic Tetracycline Resistance in Mycobacterium abscessus Are Conferred by a Tetracycline-Modifying Monooxygenase. Rudra P; Hurst-Hess K; Lappierre P; Ghosh P Antimicrob Agents Chemother; 2018 Jun; 62(6):. PubMed ID: 29632012 [TBL] [Abstract][Full Text] [Related]
30. Dissemination and prevalence of plasmid-mediated high-level tigecycline resistance gene Zhang S; Wen J; Wang Y; Wang M; Jia R; Chen S; Liu M; Zhu D; Zhao X; Wu Y; Yang Q; Huang J; Ou X; Mao S; Gao Q; Sun D; Tian B; Cheng A Front Microbiol; 2022; 13():969769. PubMed ID: 36246244 [TBL] [Abstract][Full Text] [Related]
31. Anti-HIV agent azidothymidine decreases Tet(X)-mediated bacterial resistance to tigecycline in Escherichia coli. Liu Y; Jia Y; Yang K; Li R; Xiao X; Wang Z Commun Biol; 2020 Apr; 3(1):162. PubMed ID: 32246108 [TBL] [Abstract][Full Text] [Related]
32. Exploring tet(X)-bearing tigecycline-resistant bacteria of swine farming environments. Li R; Peng K; Li Y; Liu Y; Wang Z Sci Total Environ; 2020 Sep; 733():139306. PubMed ID: 32446072 [TBL] [Abstract][Full Text] [Related]
33. In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936). Petersen PJ; Jacobus NV; Weiss WJ; Sum PE; Testa RT Antimicrob Agents Chemother; 1999 Apr; 43(4):738-44. PubMed ID: 10103174 [TBL] [Abstract][Full Text] [Related]
34. Occurrence of tetracycline resistance genes among Escherichia coli isolates from the phase 3 clinical trials for tigecycline. Tuckman M; Petersen PJ; Howe AY; Orlowski M; Mullen S; Chan K; Bradford PA; Jones CH Antimicrob Agents Chemother; 2007 Sep; 51(9):3205-11. PubMed ID: 17620376 [TBL] [Abstract][Full Text] [Related]
35. Large-Scale Analysis of Fitness Cost of Tang F; Cai W; Jiang L; Wang Z; Liu Y Front Cell Infect Microbiol; 2022; 12():798802. PubMed ID: 35719358 [TBL] [Abstract][Full Text] [Related]